keyword
MENU ▼
Read by QxMD icon Read
search

Atomoxetine

keyword
https://www.readbyqxmd.com/read/29048739/pharmacotherapy-for-social-anxiety-disorder-sand
#1
REVIEW
Taryn Williams, Coenraad J Hattingh, Catherine M Kariuki, Sean A Tromp, Anton J van Balkom, Jonathan C Ipser, Dan J Stein
BACKGROUND: Recognition is growing that social anxiety disorder (SAnD) is a chronic and disabling disorder, and data from early trials demonstrate that medication may be effective in its treatment. This systematic review is an update of an earlier review of pharmacotherapy of SAnD. OBJECTIVES: To assess the effects of pharmacotherapy for social anxiety disorder in adults and identify which factors (methodological or clinical) predict response to treatment. SEARCH METHODS: We searched the Cochrane Common Mental Disorders Controlled Trials Register (CCMDCTR-Studies and CCMDCTR-References) to 17 August 2015...
October 19, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29022125/parent-stress-in-a-randomized-clinical-trial-of-atomoxetine-and-parent-training-for-children-with-autism-spectrum-disorder
#2
Luc Lecavalier, Xueliang Pan, Tristram Smith, Benjamin L Handen, L Eugene Arnold, Laura Silverman, Rameshwari V Tumuluru, Jill Hollway, Michael G Aman
We previously reported a 2 × 2 randomized clinical trial of atomoxetine (ATX) and parent training (PT) for attention deficit hyperactivity disorder (ADHD) symptoms and behavioral noncompliance in 128 children with autism spectrum disorder, ages 5-14 years. Children were randomized to one of four conditions: ATX alone, placebo alone, ATX + PT, or PT + placebo. Both ATX and PT improved some indices of ADHD and behavioral compliance. In this report, we describe parent stress over time and across conditions...
October 11, 2017: Journal of Autism and Developmental Disorders
https://www.readbyqxmd.com/read/28984477/pediatric-pharmacoepidemiology-safety-and-effectiveness-of-medicines-for-adhd
#3
Antonio Clavenna, Maurizio Bonati
Attention-deficit hyperactivity disorder (ADHD) is a common neurobehavioral disorder in children and adolescents that comprises core symptoms of developmentally inappropriate levels of inattention and/or hyperactivity and impulsivity. Stimulant (methylphenidate, amphetamines) and non stimulant (atomoxetine, clonidine and guanfacine) are the treatment usually prescribed for ADHD. Area covered: This review covers the safety of ADHD medications in children and adolescents. MEDLINE, EMBASE and PsycINFO databases were searched with the aim to retrieve prospective studies that monitored the incidence of adverse events (AEs) in children receiving drug therapy for ADHD...
October 12, 2017: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/28974127/a-signature-of-attention-elicited-electrocortical-activity-distinguishes-response-from-non-response-to-the-non-stimulant-atomoxetine-in-children-and-adolescents-with-adhd
#4
Kristi R Griffiths, Barbora G Jurigova, John E Leikauf, Donna Palmer, Simon D Clarke, Tracey W Tsang, Erdahl T Teber, Michael R Kohn, Leanne M Williams
OBJECTIVE: Atomoxetine has several characteristics that make it an attractive alternative to stimulants for treating ADHD, but there are currently no tests identifying individuals for whom the medication should be a first-line option. METHOD: Within the ADHD Controlled Trial Investigation Of a Non-stimulant (ACTION) study, we examined neuro-cortical activity in 52 youth with ADHD. Baseline event-related potentials (ERP) were compared between those who subsequently responded to 6 weeks of atomoxetine versus those who did not...
October 1, 2017: Journal of Attention Disorders
https://www.readbyqxmd.com/read/28861456/atomoxetine-in-abstinent-cocaine-users-sex-differences
#5
Elise E DeVito, Aryeh I Herman, Noah S Konkus, Huiping Zhang, Mehmet Sofuoglu
Data presented are from a sex-differences secondary analysis of a human laboratory investigation of single doses of atomoxetine (40 mg and 80 mg) versus placebo in abstinent individuals with cocaine use disorders (CUD). Subjective drug effects, cognitive performance and cardiovascular measures were assessed. The primary atomoxetine dose analyses (which do not consider sex as a factor) are reported in full elsewhere (DeVito et al., 2017) [1].
October 2017: Data in Brief
https://www.readbyqxmd.com/read/28860113/physiologically-based-pharmacokinetic-model-of-the-cyp2d6-probe-atomoxetine-extrapolation-to-special-populations-and-drug-drug-interactions
#6
Weize Huang, Mariko Nakano, Jennifer Sager, Isabelle Ragueneau-Majlessi, Nina Isoherranen
Physiologically based pharmacokinetic (PBPK) modeling of drug disposition and drug-drug interactions (DDIs) has become a key component of drug development. PBPK modeling has also been considered as an approach to predict drug disposition in special populations. However, whether models developed and validated in healthy populations can be extrapolated to special populations is not well established. The goal of this study was to determine whether a drug-specific PBPK model validated using healthy populations could be used to predict drug disposition in specific populations and in organ impairment patients...
November 2017: Drug Metabolism and Disposition: the Biological Fate of Chemicals
https://www.readbyqxmd.com/read/28844345/the-effect-of-atomoxetine-a-selective-norepinephrine-reuptake-inhibitor-on-respiratory-arrest-and-cardiorespiratory-function-in-the-dba-1-mouse-model-of-sudep
#7
Haiting Zhao, Joseph F Cotten, Xiaoyan Long, Hua-Jun Feng
Sudden unexpected death in epilepsy (SUDEP) is a significant public health burden. The mechanisms of SUDEP are elusive, although cardiorespiratory dysfunction is a likely contributor. Clinical and animal studies indicate that seizure-induced respiratory arrest (S-IRA) is the primary event leading to death in many SUDEP cases. Our prior studies demonstrated that intraperitoneal (IP) injection of atomoxetine, a norepinephrine reuptake inhibitor (NRI) widely used to treat attention deficit hyperactivity disorder, suppresses S-IRA in DBA/1 mice...
August 22, 2017: Epilepsy Research
https://www.readbyqxmd.com/read/28837827/pharmacotherapy-of-emotional-dysregulation-in-adults-with-adhd-a-systematic-review-and-meta-analysis
#8
REVIEW
Francesca Lenzi, Samuele Cortese, Joseph Harris, Gabriele Masi
Emotional dysregulation (ED) is a dysfunction in modifying an emotional state in an adaptive and goal oriented way, with excitability, ease anger, and mood lability. It is present in up to 70% of adults with ADHD, regardless of other comorbidities, and substantially worsens the psychosocial outcomes of the disorder. Besides fronto-parietal circuits mediating top-down control, brain regions involved in bottom-up processes (e.g., amygdala, orbitofrontal cortex, and ventral striatum) are implicated in ED. We performed a systematic review/meta-analysis of double-blind randomized controlled trials of ADHD medications to assess their effects on ED in adults with ADHD...
August 25, 2017: Neuroscience and Biobehavioral Reviews
https://www.readbyqxmd.com/read/28836895/correlations-between-clinical-trial-outcomes-based-on-symptoms-functional-impairments-and-quality-of-life-in-children-and-adolescents-with-adhd
#9
David R Coghill, Alain Joseph, Vanja Sikirica, Mark Kosinski, Caleb Bliss, Michael Huss
OBJECTIVE: To assess relationships between treatment-associated changes in measures of ADHD symptoms, functional impairments, and health-related quality of life in children and adolescents with ADHD. METHOD: Pearson correlation coefficients were calculated post hoc for changes from baseline to endpoint in outcomes of one randomized, placebo- and active-controlled trial of lisdexamfetamine (osmotic-release methylphenidate reference) and one of guanfacine extended-release (atomoxetine reference)...
August 1, 2017: Journal of Attention Disorders
https://www.readbyqxmd.com/read/28807495/the-colorful-spectrum-of-tourette-syndrome-and-its-medical-surgical-and-behavioral-therapies
#10
Jan Roth
Tourette syndrome (TS) is a common neuropsychiatric disorder, more common in males than females, with onset before age 18. TS is characterized by multiple motor tics and one or more vocal/phonic tics, persisting for more than a year. Tics are unvoluntary, abrupt, rapid, repetitive, but non-rhythmic movements or sounds (vocalizations). They are preceded by an inner urge. Tics can be temporarily suppressed, but this leads to a powerful re-emergence. The performance of tics results in immediate but transient relief...
August 10, 2017: Parkinsonism & related Disorders
https://www.readbyqxmd.com/read/28806024/atomoxetine-pharmacogenetics-lessons-learned
#11
David Ermer, Tamara Vik
No abstract text is available yet for this article.
July 2017: South Dakota Medicine: the Journal of the South Dakota State Medical Association
https://www.readbyqxmd.com/read/28730282/blockade-of-%C3%AE-2-adrenergic-receptors-in-prelimbic-cortex-impact-on-cocaine-self-administration-in-adult-spontaneously-hypertensive-rats-following-adolescent-atomoxetine-treatment
#12
Britahny M Baskin, Bríd Á Nic Dhonnchadha, Linda P Dwoskin, Kathleen M Kantak
RATIONALE: Research with the spontaneously hypertensive rat (SHR) model of attention deficit/hyperactivity disorder demonstrated that chronic methylphenidate treatment during adolescence increased cocaine self-administration established during adulthood under a progressive ratio (PR) schedule. Compared to vehicle, chronic atomoxetine treatment during adolescence failed to increase cocaine self-administration under a PR schedule in adult SHR. OBJECTIVES: We determined if enhanced noradrenergic transmission at α2-adrenergic receptors within prefrontal cortex contributes to this neutral effect of adolescent atomoxetine treatment in adult SHR...
July 20, 2017: Psychopharmacology
https://www.readbyqxmd.com/read/28716656/atomoxetine-in-abstinent-cocaine-users-cognitive-subjective-and-cardiovascular-effects
#13
Elise E DeVito, Aryeh I Herman, Noah S Konkus, Huiping Zhang, Mehmet Sofuoglu
No pharmacotherapies are approved for the treatment of cocaine use disorders (CUD). Behavioral treatments for CUD are efficacious for some individuals, but recovery rates from CUD remain low. Cognitive impairments in CUD have been linked with poorer clinical outcomes. Cognitive enhancing pharmacotherapies have been proposed as promising treatments for CUD. Atomoxetine, a norepinephrine transporter inhibitor, shows potential as a treatment for CUD based on its efficacy as a cognitive enhancer in other clinical populations and impact on addictive processes in preclinical and human laboratory studies...
August 2017: Pharmacology, Biochemistry, and Behavior
https://www.readbyqxmd.com/read/28712042/erratum-to-effects-of-atomoxetine-on-attention-in-wistar-rats-treated-with-the-neurotoxin-n-2-chloroethyl-n-ethyl-2-bromobenzylamine-dsp4
#14
Joachim Hauser, Andreas Reissmann, Thomas-A Sontag, Oliver Tucha, Klaus W Lange
No abstract text is available yet for this article.
July 15, 2017: Attention Deficit and Hyperactivity Disorders
https://www.readbyqxmd.com/read/28700715/the-pharmacological-and-non-pharmacological-treatment-of-attention-deficit-hyperactivity-disorder-in-children-and-adolescents-a-systematic-review-with-network-meta-analyses-of-randomised-trials
#15
Ferrán Catalá-López, Brian Hutton, Amparo Núñez-Beltrán, Matthew J Page, Manuel Ridao, Diego Macías Saint-Gerons, Miguel A Catalá, Rafael Tabarés-Seisdedos, David Moher
BACKGROUND: Attention deficit hyperactivity disorder (ADHD) is one of the most commonly diagnosed psychiatric disorders in childhood. A wide variety of treatments have been used for the management of ADHD. We aimed to compare the efficacy and safety of pharmacological, psychological and complementary and alternative medicine interventions for the treatment of ADHD in children and adolescents. METHODS AND FINDINGS: We performed a systematic review with network meta-analyses...
2017: PloS One
https://www.readbyqxmd.com/read/28661714/early-initiation-of-amphetamine-type-stimulants-ats-use-associated-with-lowered-cognitive-performance-among-individuals-with-co-occurring-opioid-and-ats-use-disorders-in-malaysia
#16
Weng-Tink Chooi, Norzarina Mohd Zaharim, Alethea Desrosiers, Imran Ahmad, Mohd Azhar Mohd Yasin, Sharifah Z Syed Jaapar, Richard S Schottenfeld, Balasingam K Vicknasingam, Marek C Chawarski
Amphetamine-type stimulants (ATS) use is increasingly prevalent in Malaysia, including among individuals who also use opioids. We evaluated cognitive functioning profiles among individuals with co-occurring opioid and ATS dependence and their lifetime patterns of drug use. Participants (N = 50) enrolling in a clinical trial of buprenorphine/naloxone treatment with or without atomoxetine completed the Raven's Standard Progressive Matrices, Rey-Osterrieth Complex Figure Test, Digit Span, Trail Making and Symbol Digit Substitution tasks...
June 29, 2017: Journal of Psychoactive Drugs
https://www.readbyqxmd.com/read/28659039/adhd-medication-and-substance-related-problems
#17
Patrick D Quinn, Zheng Chang, Kwan Hur, Robert D Gibbons, Benjamin B Lahey, Martin E Rickert, Arvid Sjölander, Paul Lichtenstein, Henrik Larsson, Brian M D'Onofrio
OBJECTIVE: Substance use disorders are major contributors to excess mortality among individuals with attention deficit hyperactivity disorder (ADHD), yet associations between pharmacological ADHD treatment and substance-related problems remain unclear. This study investigated concurrent and long-term associations between ADHD medication treatment and substance-related events. METHOD: The authors analyzed 2005-2014 commercial health care claims from 2,993,887 (47...
September 1, 2017: American Journal of Psychiatry
https://www.readbyqxmd.com/read/28657141/neural-correlates-of-atomoxetine-improving-inhibitory-control-and-visual-processing-in-drug-na%C3%A3-ve-adults-with-attention-deficit-hyperactivity-disorder
#18
Li-Ying Fan, Tai-Li Chou, Susan Shur-Fen Gau
Atomoxetine improves inhibitory control and visual processing in healthy volunteers and adults with attention-deficit/hyperactivity disorder (ADHD). However, little is known about the neural correlates of these two functions after chronic treatment with atomoxetine. This study aimed to use the counting Stroop task with functional magnetic resonance imaging (fMRI) and the Cambridge Neuropsychological Test Automated Battery (CANTAB) to investigate the changes related to inhibitory control and visual processing in adults with ADHD...
June 28, 2017: Human Brain Mapping
https://www.readbyqxmd.com/read/28647012/striatal-activation-predicts-differential-therapeutic-responses-to-methylphenidate-and-atomoxetine
#19
Kurt P Schulz, Anne-Claude V Bédard, Jin Fan, Thomas B Hildebrandt, Mark A Stein, Iliyan Ivanov, Jeffrey M Halperin, Jeffrey H Newcorn
OBJECTIVE: Methylphenidate has prominent effects in the dopamine-rich striatum that are absent for the selective norepinephrine transporter inhibitor atomoxetine. This study tested whether baseline striatal activation would predict differential response to the two medications in youth with attention-deficit/hyperactivity disorder (ADHD). METHOD: A total of 36 youth with ADHD performed a Go/No-Go test during functional magnetic resonance imaging at baseline and were treated with methylphenidate and atomoxetine using a randomized cross-over design...
July 2017: Journal of the American Academy of Child and Adolescent Psychiatry
https://www.readbyqxmd.com/read/28646732/effects-of-stimulants-and-atomoxetine-on-emotional-lability-in-adults-a-systematic-review-and-meta-analysis
#20
T R Moukhtarian, R E Cooper, E Vassos, P Moran, P Asherson
BACKGROUND: Emotional lability (EL) is an associated feature of attention-deficit/hyperactivity disorder (ADHD) in adults, contributing to functional impairment. Yet the effect of pharmacological treatments for ADHD on EL symptoms is unknown. We conducted a systematic review and meta-analysis to examine the effects of stimulants and atomoxetine on symptoms of EL and compare these with the effects on core ADHD symptoms. METHODS: A systematic search was conducted on the databases Embase, PsychInfo, and Ovid Medline(®) and the clinicaltrials...
May 25, 2017: European Psychiatry: the Journal of the Association of European Psychiatrists
keyword
keyword
4829
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"